NCT01890122 - Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes | Biotech Hunter

Enrollment

647

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

October 31, 2015

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin

Alogliptin tablets

DRUG

Metformin HCl

Metformin HCl capsules

DRUG

Alogliptin and Metformin Fixed-Dose Combination (FDC)

Alogliptin and metformin FDC tablets

DRUG

Alogliptin Placebo

Alogliptin placebo-matching tablets

DRUG

Metformin Placebo

Metformin placebo-matching capsules

DRUG

Alogliptin and Metformin FDC Placebo

Alogliptin and metformin FDC placebo-matching tablets

Trial Locations (45)

Unknown

Beijing

Fuzhou

Xiamen

Guangzhou

Nanning

Guiyang

Hengshui

Shijiazhuang

Shiyan

Wuhan

Changsha

Yueyang

Changzhou

Nanjing

Suzhou

Nanchang

Changchun

Shenyang

Xi’an

Chengdu

Wenzhou

Beijing

Shanghai

Tianjin

Johor Bahru

Alor Star

Kubang Kerian

Putrajaya

Kampung Baharu Nilai

Seremban

Tampin

Bagan Serai

Ipoh

Petaling Jaya

Shah Alam

Goyang-si

Seongnam-si

Suwon

Busan

Seoul

Kaohsiung City

New Taipei City

Taichung

Taipei